US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% AMD $633.91 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Articles published by Pharming Group N.V.

< Previous 1 2 Next >
News headline image
Pharming Group to participate in March investor conference
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to report fourth quarter and full year 2024 financial results on March 13
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to participate in February investor conference
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming announces public cash offer to the shareholders of Abliva AB
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming announces positive topline data in pediatric clinical trial of leniolisib
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to participate in November investor conference
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group reports third quarter 2024 financial results and provides business update
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to report third quarter 2024 financial results on October 24
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to participate in September investor conferences
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group reports second quarter and first half 2024 financial results and provides business update
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to report second quarter and first half 2024 financial results on August 1
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to participate in June investor conferences
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to participate in May investor conference
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group reports first quarter 2024 financial results and provides business update
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to participate in April investor conferences
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group reports fourth quarter and full year 2023 financial results
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to participate in February investor conferences
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to participate in November investor conferences
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group reports third quarter 2023 financial results
From Pharming Group N.V.
Via GlobeNewswire
News headline image
Pharming Group to report third quarter 2023 financial results on October 26
From Pharming Group N.V.
Via GlobeNewswire
< Previous 1 2 Next >